Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Magnetic Cell Delivery for the Treatment of Geographic Atrophy
Author Affiliations & Notes
  • Chris Douglas
    Emmecell, Menlo Park, California, United States
  • Roger Goldberg
    Bay Area Retina Associates, Walnut Creek, California, United States
  • Noelia J Kunzevitzky
    Emmecell, Menlo Park, California, United States
  • Jeffrey Louis Goldberg
    Byers Eye Institute, Stanford University, Stanford, California, United States
  • Footnotes
    Commercial Relationships   Chris Douglas Emmecell, Code E (Employment); Roger Goldberg Emmecell, Code S (non-remunerative); Noelia Kunzevitzky Emmecell, Code E (Employment); Jeffrey Goldberg Emmecell, Code O (Owner)
  • Footnotes
    Support  n/a
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 3780. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chris Douglas, Roger Goldberg, Noelia J Kunzevitzky, Jeffrey Louis Goldberg; Magnetic Cell Delivery for the Treatment of Geographic Atrophy. Invest. Ophthalmol. Vis. Sci. 2024;65(7):3780.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Most cell therapy technologies lack the ability to localize cells to their correct target. Subretinal injection of stem cell derived-RPE cells is being evaluated in phase I/II clinical trials for geographic atrophy (GA). The success of this approach is dependent on the identity of the cells injected, and their ability to be delivered to and retained at their target location. Here we evaluate the feasibility of using magnetic cell delivery to enhance iPSC-RPE cell transplant for the treatment of GA.

Methods : Induced pluripotent stem cells (Infinity Biologic #5200) were differentiated into retinal pigment epithelial (RPE) cells (iPSC-RPE) and labeled using magnetic nanoparticles. Viability and cell identity of magnetic RPE cells were evaluated by flow cytometry using markers for mature RPE and retinal progenitor cells. Labeling efficiency was quantified and magnetic iPSC-RPE cells were selected using a magnetic column.
Magnetic iPSC-RPE cells were labeled with FITC-DEAE-Dextran, and cells were transplanted using a 25G/38G cannula into the subretinal space of freshly harvested rabbit eyes. A neodymium magnet was positioned on the opposite side of the choroid for 2 sec to 2 min to facilitate cell localization, after which the bleb was aspirated. The eyes were fixed in 4% paraformaldehyde, and retinas and Bruch’s membrane were imaged to confirm distribution and retention of the magnetic iPSC-RPE cells using an anti-human CD166-PE or magnetic particle-specific antibody.

Results : At harvesting, iPSC-RPE cells were >85% viable and positive for identity markers BEST1, RPE65 and CD56. Labeling these cells with magnetic nanoparticles did not affect viability or identity. Magnetic selection recovered ~95% of the cells, indicating high labeling efficiency. Subretinal injection of magnetic RPE cells in combination with an external magnetic force significantly improved retention and distribution of the donor cells.

Conclusions : Magnetic cell delivery of iPSC-RPE cells may be an effective technique for improving retention and distribution of RPE cells in the subretinal space and lead to better vision restoration in geographic atrophy.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×